372
Views
8
CrossRef citations to date
0
Altmetric
Editorial

Future directions in endometriosis treatment: discovery and development of novel inhibitors of estrogen biosynthesis

, , , &
Pages 501-504 | Received 06 Mar 2019, Accepted 09 May 2019, Published online: 17 May 2019

References

  • Vercellini P, Vigano P, Somigliana E, et al. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014 May;10(5):261–275. PubMed PMID: 24366116; eng.
  • Kitawaki J, Kado N, Ishihara H, et al. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol. 2002 Dec;83(1–5):149–155. PubMed PMID: 12650711.
  • Noble LS, Takayama K, Zeitoun KM, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab. 1997 Feb;82(2):600–606. PubMed PMID: 9024261.
  • Tsai SJ, Wu MH, Lin CC, et al. Regulation of steroidogenic acute regulatory protein expression and progesterone production in endometriotic stromal cells. J Clin Endocrinol Metab. 2001 Dec;86(12):5765–5773. PubMed PMID: 11739437.
  • Ferrero S, Remorgida V, Maganza C, et al. Aromatase and endometriosis: estrogens play a role. Ann N Y Acad Sci. 2014 May;1317:17–23. PubMed PMID: 24738993.
  • Ferrero S, Barra F, Leone Roberti Maggiore U. Current and emerging therapeutics for the management of endometriosis. Drugs. 2018 Jul;78(10):995–1012. PubMed PMID: 29946962.
  • Barra F, Grandi G, Tantari M, et al. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin Biol Ther. 2019 Feb 14;1–18. PubMed PMID: 30763525. DOI:10.1080/14712598.2019.1581761
  • Barra F, Scala C, Ferrero S. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain. Drugs Today (Barc). 2019;55(4):1–10.
  • Konings G, Brentjens L, Delvoux B, et al. Intracrine regulation of estrogen and other sex steroid levels in endometrium and non-gynecological tissues; pathology, physiology, and drug discovery. Front Pharmacol. 2018;9:940. PubMed PMID: 30283331; PubMed Central PMCID: PMCPMC6157328.
  • Rizner TL. Estrogen metabolism and action in endometriosis. Mol Cell Endocrinol. 2009 Aug 13;307(1–2):8–18. PubMed PMID: 19524121.
  • Mueller JW, Gilligan LC, Idkowiak J, et al. The regulation of steroid action by sulfation and desulfation. Endocr Rev. 2015 Oct;36(5):526–563. PubMed PMID: 26213785; PubMed Central PMCID: PMCPMC4591525.
  • Huhtinen K, Stahle M, Perheentupa A, et al. Estrogen biosynthesis and signaling in endometriosis. Mol Cell Endocrinol. 2012 Jul 25;358(2):146–154. PubMed PMID: 21875644.
  • Rizner TL. The important roles of steroid sulfatase and sulfotransferases in gynecological diseases. Front Pharmacol. 2016;7:30. PubMed PMID: 26924986; PubMed Central PMCID: PMCPMC4757672.
  • Ferrero S, Gillott DJ, Venturini PL, et al. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review [Review]. Reprod Biol Endocrinol. 2011;9. DOI:10.1186/1477-7827-9-89
  • Dunselman GAJ, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis [Article]. Hum Reprod. 2014;29(3):400–412.
  • Piccinato CA, Malvezzi H, Gibson DA, et al. SULFATION PATHWAYS: contribution of intracrine oestrogens to the aetiology of endometriosis. J Mol Endocrinol. 2018 Aug;61(2):T253–T270. PubMed PMID: 30030390.
  • Purohit A, Fusi L, Brosens J, et al. Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy. Hum Reprod. 2008 Feb;23(2):290–297. PubMed PMID: 18056119.
  • Colette S, Defrere S, Lousse JC, et al. Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model. Hum Reprod. 2011 Jun;26(6):1362–1370. PubMed PMID: 21441545.
  • Pohl O, Bestel E, Gotteland JP. Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014 Oct;21(10):1256–1265. PubMed PMID: 24604234.
  • Smuc T, Hevir N, Ribic-Pucelj M, et al. Disturbed estrogen and progesterone action in ovarian endometriosis. Mol Cell Endocrinol. 2009 Mar 25;301(1–2):59–64. PubMed PMID: 18762229.
  • Maltais R, Trottier A, Roy J, et al. Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17beta-HSD1 for breast cancer and endometriosis treatments. J Steroid Biochem Mol Biol. 2018 Apr;178:167–176. PubMed PMID: 29248731.
  • Penning TM. AKR1C3 (type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase): roles in malignancy and endocrine disorders. Mol Cell Endocrinol. 2018 Sep 18. PubMed PMID: 30012349. DOI:10.1016/j.mce.2018.07.002
  • Sinreih M, Anko M, Kene NH, et al. Expression of AKR1B1, AKR1C3 and other genes of prostaglandin F2alpha biosynthesis and action in ovarian endometriosis tissue and in model cell lines. Chem Biol Interact. 2015 Jun 5;234:320–331. PubMed PMID: 25446850.
  • Penning TM. Aldo-keto reductase (AKR) 1C3 inhibitors: a patent review. Expert Opin Ther Pat. 2017 Dec;27(12):1329–1340. PubMed PMID: 28895472; PubMed Central PMCID: PMCPMC5724044.
  • Barra F, Scala C, Mais V, et al. Investigational drugs for the treatment of endometriosis, an update on recent developments. Expert Opin Investig Drugs. 2018 Apr 30. PubMed PMID: 29708812. DOI:10.1080/13543784.2018.1471135

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.